TL;DR
Vitreoscilla filiformis is a non-photosynthetic bacterium first isolated from thermal spring water in France. The lysate (heat-killed extract) is used in several sensitive-skin and atopic-dermatitis creams, most notably L’Oreal-group products under the La Roche-Posay and Vichy labels. The clinical evidence for soothing effects in atopic skin is decent. The marketing rarely tells you what it actually is.
One of the more unusual ingredients hiding on sensitive-skin product labels in 2026 is a bacterium with a name almost nobody recognizes. Vitreoscilla filiformis. It shows up on La Roche-Posay’s Lipikar line, Vichy’s Aqualia and Mineral 89 lines, and a handful of other European-developed sensitive-skin formulations. The label often says aqua thermalis or thermal spring water alongside the bacterium-derived ingredient. The marketing rarely explains the connection.
The connection is interesting. The bacterium came from the water. The lysate of the bacterium does measurable work in atopic and sensitive skin. The product traces a clean line from a specific French thermal spring to a peer-reviewed dermatology literature to the cream on your shelf.
What V. filiformis actually is
Vitreoscilla filiformis is a filamentous, non-photosynthetic, gram-negative bacterium. The genus Vitreoscilla was first described in the late 19th century, and V. filiformis was isolated from the thermal waters of La Roche-Posay in central France, where the bacterium grows in the mineral-rich, low-temperature spring water that gives the eponymous skincare line its source ingredient.
The bacterium itself does not appear on consumer skincare labels. What appears is the lysate: heat-killed, processed extract of the bacterium grown in controlled culture. The extract retains the cell wall components, lipopolysaccharides, and metabolic byproducts that produce the dermatological effect, without the live organism.
This is a postbiotic preparation in the strict sense. The bacterium is non-viable in the finished product. The mechanism is through the microbial-derived molecules acting on skin receptors and immune cells.
What the research supports
The V. filiformis lysate has one of the longer clinical literatures of any postbiotic skincare ingredient. The research started in the 1990s with L’Oreal-funded work characterizing the immunomodulatory effects on keratinocytes and Langerhans cells. The work expanded in the 2000s and 2010s into atopic dermatitis trials, sensitive-skin formulations, and barrier-recovery studies.
A 2014 review by Gueniche and colleagues in Beneficial Microbes summarized the V. filiformis lysate evidence: anti-inflammatory effects in vitro and in vivo, modulation of Toll-like receptor signaling, reduction of pruritus in atopic patients, and barrier-supportive effects in repeated-use studies. The effect sizes are modest but consistent.
A 2008 randomized double-blind trial published in the British Journal of Dermatology tested a V. filiformis lysate cream against vehicle in 60 patients with atopic dermatitis over 30 days. The active group showed significantly greater reduction in eczema severity, pruritus, and topical steroid use. The methodology was solid for the time and the trial has been cited as a foundation for the ingredient’s clinical case.
The contrarian H2: the marketing is doing the ingredient a disservice
Most consumers buying La Roche-Posay or Vichy products in 2026 do not know that one of the active mechanisms is a bacterium isolated from a French spring. The marketing emphasizes the thermal water itself, the brand heritage, the dermatology endorsements. The ingredient label says aqua thermalis. The bacterium-derived component is listed under various trade names that do not flag the biological origin clearly.
This is partly regulatory caution and partly marketing strategy. Live bacteria on the face is a hard sell to most consumers. Heat-killed bacterial lysate is a slightly easier sell. Postbiotic skincare is the easiest sell. The same ingredient, framed three different ways, lands differently.
The disservice is that consumers do not get to connect the clinical evidence to the ingredient when they buy the product. The dermatology research on V. filiformis lysate is genuinely useful. The buyer who knows the connection can make an informed choice. The buyer who reads the marketing is buying soothing thermal water without knowing why it soothes.
This is one of the small reasons I prefer ingredient-forward labeling. A consumer who knows what postbiotic lysate is, and what V. filiformis specifically is, can make a much better routine decision than one who reads brand marketing.
The real numbers
The 2008 Gueniche trial in British Journal of Dermatology measured a 36 percent reduction in SCORAD score in the V. filiformis lysate group at day 30, compared with 18 percent in the vehicle group. The reduction in pruritus visual analog score was 41 percent versus 21 percent. The differences were statistically significant.
The 2014 review in Beneficial Microbes synthesized 8 clinical trials on V. filiformis lysate, finding consistent effect sizes of 25 to 45 percent improvement on various atopic dermatitis severity indices compared with vehicle. The variability across trials reflects methodological differences rather than inconsistent ingredient performance.
The National Library of Medicine PubMed database lists more than 40 papers on V. filiformis and its dermatological applications, making it one of the better-documented postbiotic ingredients in skincare.
Where to find it on labels
The ingredient is listed under several names depending on the formulation and regulatory market.
Vitreoscilla filiformis lysate is the explicit name and the easiest to identify.
Aqua thermalis or thermal spring water often appears alongside the lysate. The water on its own is mineral-rich but the active component is the bacterial extract.
The La Roche-Posay Lipikar line, Vichy Aqualia and Mineral 89 lines, Avene Tolerance Extreme line (using a different but related ingredient called Avene Aqua Thermale), and several Cerave-adjacent European formulations include the ingredient.
The pricing range is broad. The same ingredient appears in $15 drugstore creams and in $65 boutique sensitive-skin formulations. The percentage and supporting formulation vary, but the active ingredient is comparable.
What this means for sensitive-skin routines
If your skin is reactive, eczema-prone, or recovering from barrier damage, V. filiformis lysate is one of the better-supported postbiotic ingredients available in 2026. The clinical evidence for soothing and barrier-supportive effects is reasonable.
The ingredient pairs well with ceramide-rich moisturizers, panthenol-containing creams, and standard barrier-repair routines. It does not replace prescription topicals for moderate to severe atopic dermatitis but can reduce flare frequency and intensity in mild to moderate cases.
For broader context on sensitive skin and barrier care, see the microbiome skincare explainer, the sensitive skin routine guide, and the barrier repair routine.
FAQ
Is V. filiformis lysate the same as a probiotic? No. It is postbiotic. The bacterium is heat-killed in the manufacturing process. The active components are the microbial molecules, not a live organism.
Can I use it daily? Yes. The ingredient has a long safety record and is formulated for daily use in sensitive-skin contexts. Tolerance issues are uncommon.
Is it suitable for use on babies and children? Some of the La Roche-Posay Lipikar formulations are specifically indicated for pediatric use and have safety data for that population. Check the specific product label.
How does it compare to ceramide moisturizers? Different mechanism, complementary effect. Ceramides rebuild barrier lipids. V. filiformis lysate modulates the inflammatory response. Using both in a routine is reasonable.
Why is the ingredient mostly in French-brand products? The original isolation was from a French thermal spring and L’Oreal group has held most of the IP and clinical development. Other manufacturers can use the ingredient, but the supply chain is concentrated.
Tag hub: More on sensitive-skin routines and soothing ingredients
Sources
Gueniche A et al. Vitreoscilla filiformis bacterial extract to improve the efficacy of emollient line A. British Journal of Dermatology 2008. Gueniche A et al. Vitreoscilla filiformis biomass improves seborrheic dermatitis and atopic dermatitis. Beneficial Microbes 2014. National Library of Medicine PubMed database on Vitreoscilla filiformis in dermatology.